C12Y 204/01011
Glycogen synthase
Official title: Glycogen(starch) synthase (2.4.1.11)
C12Y204/01011 (Glycogen synthase) appears on 9 US grants and 19 published applications in this corpus.
Search patents in C12Y- Granted patents
- 9
- Published applications
- 19
- Assignees
- 15
- Inventors
- 61
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 2 |
| 2020 | 1 | 0 |
| 2021 | 0 | 3 |
| 2022 | 0 | 3 |
| 2023 | 4 | 3 |
| 2024 | 0 | 2 |
| 2025 | 1 | 5 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for inhibiting GYS2 expression27 Jan 2026US 12,534,730 B2Novo Nordisk A/S
- Glycogen-null methanotrophs and uses thereof25 Feb 2025US 12,234,445 B2Calysta, Inc.
- Polypeptide and nucleic acid capable of changing amylose content (AC) in plant, and use thereof21 Nov 2023US 11,820,991 B2Shandong Shunfeng Biotechnology Co., Ltd.
- Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides31 Oct 2023US 11,801,311 B2Genzyme Corporation
- Polypeptide and nucleic acid capable of changing amylose content (ac) in plant, and use thereof25 Jul 2023US 11,708,579 B2Shandong Shunfeng Biotechnology Co., Ltd.
- Compositions and Methods for GYS1 Inhibition4 Dec 2025US 2025/0368997 A1ARO Biotherapeutics Company
- Compounds and methods for reducing glycogen synthase 113 Nov 2025US 2025/0346907 A1Ionis Pharmaceuticals, Inc.
- Compositions and methods for modulating mrna splicing13 Feb 2025US 2025/0051780 A1Entrada Therapeutics, Inc.
- Compounds and methods for modulating glycogen synthase 113 Feb 2025US 2025/0051781 A1Ionis Pharmaceuticals, Inc.
- Rnai therapy for apbd and lafora disease9 Jan 2025US 2025/0011791 A1Board of Regents, The University of Texas System
Most cited
By later US patents